# Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer

> **NCT03742713** · PHASE2 · COMPLETED · sponsor: **Cristal Therapeutics** · enrollment: 25 (actual)

## Conditions studied

- Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** CPC634 (CriPec® docetaxel)

## Key facts

- **NCT ID:** NCT03742713
- **Lead sponsor:** Cristal Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03742713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03742713, "Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03742713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*